Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to investigate the effects of nivolumab when given under the skin with or without rHuPH20. This study will include participants with 1 of the following advanced or metastatic tumors approved for treatment with nivolumab monotherapy: - non-small cell lung cancer (NSCLC) - renal cell carcinoma (RCC) - unresectable or metastatic melanoma - hepatocellular carcinoma (HCC) - microsatellite instability-high or mismatch repair deficient colorectal cancer (MSI-H/dMMR CRC) - in Part B, other solid tumors may be considered at the discretion of the Clinical Trial Physician - In addition to the above tumors, Part E will also include participants with metastatic urothelial carcinoma (mUC).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03656718
Study type Interventional
Source Bristol-Myers Squibb
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date October 31, 2018
Completion date March 7, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Completed NCT00377520 - A Trial for Patients With Advanced/Recurrent Endometrial Cancer Phase 2
Active, not recruiting NCT05602935 - Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Phase 2
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Recruiting NCT05322486 - Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
Recruiting NCT04566952 - Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Phase 2
Recruiting NCT05770102 - DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Phase 2/Phase 3
Recruiting NCT01917279 - Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC Phase 3
Recruiting NCT01427400 - The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction Phase 4
Completed NCT01472146 - ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer Phase 2
Completed NCT00050414 - A Study of Trabectedin in Patients With Advanced Ovarian Cancer Phase 2
Active, not recruiting NCT01037049 - Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks Phase 2
Recruiting NCT04556071 - Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer Phase 2
Active, not recruiting NCT01968109 - An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Phase 1/Phase 2
Recruiting NCT02960724 - uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Phase 2
Completed NCT00562224 - Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients Phase 1
Completed NCT04679675 - Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial N/A
Completed NCT04080843 - Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients Phase 2
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Not yet recruiting NCT01556815 - Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma Phase 2